Search

396 Result(s)
Sort by

Partnering Vanderbilt WCNDD

Partnering Vanderbilt WCNDD

Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Our culture

Our culture

Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.
founding-member-of-QUTAC

founding-member-of-QUTAC

Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Lothar Halmer

Lothar Halmer

Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
Anna Race

Anna Race

Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.
Saving Stroke Patients around the world

Saving Stroke Patients around the world

Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.